Community Practice Connections: Optimizing Outcomes in HER2-Positive Breast Cancer: Emerging Evidence and Practical Strategies in Early-Stage Treatment Settings
WebcastFaculty
OVERVIEW
Community Practice Connections: Optimizing Outcomes in HER2-Positive Breast Cancer: Emerging Evidence and Practical Strategies in Early-Stage Treatment Settings is organized by Physicians Education Resource, LLC (PER) and will be held during May 31, 2017 - May 31, 2018.
The target audience for this medical event is directed toward medical oncologists, surgeons, pathologists, and fellows. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of breast cancer are also invited to participate. This CME Conference has been approved for a maximum of 2.00 AMA PRA Category 1 Credits.
Conference Objectives :
Upon completion of this activity, you should be better prepared to:
• Determine current outcomes with standard adjuvant treatment of HER2+ breast cancer, and identify clinically unmet needs that remain in the field
• Identify testing that can be utilized to inform clinical decision making for patients with early-stage, HER2+ breast cancer
• Describe key findings from recent clinical trials conducted in HER2+ breast cancer that has evaluated extended adjuvant approaches
• Place key findings from clinical trials in the context of best practices that can translated and practically applied to manage early-stage, HER2+ breast cancer
Additional details will be posted as soon as they are available.
The target audience for this medical event is directed toward medical oncologists, surgeons, pathologists, and fellows. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of breast cancer are also invited to participate. This CME Conference has been approved for a maximum of 2.00 AMA PRA Category 1 Credits.
Conference Objectives :
Upon completion of this activity, you should be better prepared to:
• Determine current outcomes with standard adjuvant treatment of HER2+ breast cancer, and identify clinically unmet needs that remain in the field
• Identify testing that can be utilized to inform clinical decision making for patients with early-stage, HER2+ breast cancer
• Describe key findings from recent clinical trials conducted in HER2+ breast cancer that has evaluated extended adjuvant approaches
• Place key findings from clinical trials in the context of best practices that can translated and practically applied to manage early-stage, HER2+ breast cancer
Additional details will be posted as soon as they are available.
SPECIALITIES
Oncology
Quick Links